The decision to halt the study is due to a discovered discrepancy between the study design and the anticipated use of the TIES product system.

A new study will be launched during late 2024.

Study to assess the safety, performance and durability of the TIES® transcutaneous titanium implant in patients requiring a permanent ileostomy.

This is a multicentre, open-label, single-arm clinical study that will assess the safety, performance and durability of the TIES® transcutaneous titanium implant in patients requiring a permanent ileostomy (a surgical procedure that involves connecting the small intestine to the skin to create an opening).

The Transcutaneous Implant Evacuation System (TIES®) is a medical device designed to enable continence control for patients who would otherwise need to wear an ileostomy bag.

Eligible subjects will undergo a conventional ileostomy procedure under general anaesthesia and have the TIES® Port implanted. To date, the TIES® has been evaluated in 11 patients in 2 clinical studies. This study aims to collect more data that will assess performance, durability, safety and the impact that the TIES® has on a patient's quality of life.

The study will enroll 50 patients across Europe that require a permanent ileostomy, including patients with ulcerative colitis, familial adenomatous polyposis coli or other diseases such as Crohn´s disease.

Study subjects are expected to participate for approximately 1 year following surgical placement of the TIES® Port. Participation will involve a screening period, surgical implantation of the device (in-patient) and scheduled follow-up assessments out to 1 year post implant.

Inclusion Criteria:

• Subject has ulcerative colitis, familial adenomatous polyposis coli or other diseases such as Crohn´s disease for whom a permanent ileostomy is indicated; or the subject has a medical need for an alternative to an existing conventional end-ileostomy, continent ileostomy or pelvic pouch; and
• Patient is a male ≥18 years of age or female ≥18 years of age (See exclusion criterion 4 regarding female with childbearing potential); and
• Signed written informed consent has been obtained prior to any study- related procedure.

Exclusion Criteria:

• Concurrent gastrointestinal fistula, parastomal or incisional hernia, or a history of recurrent gastrointestinal fistula, recurrent parastomal hernia(s), and/or recurrent incisional hernia(s).
• Patients with undetermined colitis.
• An acute episode of Crohn´s disease occurring during the last three months before the operation
• Females who are of childbearing potential and do not wish to use birth control measures for the duration of the study
• Patients receiving immunosuppressives, oncologic treatment or anticoagulants.
• Any clinically significant, abnormal, baseline laboratory result which in the opinion of the surgeon, affects the patient's suitability for the study or puts the patient at risk if he/she undergoes surgery
• Severe illness which, in the opinion of the surgeon may put the patient at risk when participating in the study or may affect the patient's ability to complete the study visits
• Condition associated with the risk of poor protocol compliance, e.g. alcoholism and/or drug abuse, dementia, self-destructive personality disorder
• Subjects with BMI ≤ 17 kg/m2 or BMI ≥ 33 kg/m2
• Participate in other clinical studies that could interfere with the result in the ongoing study

Currently no plan to share IPD but OstomyCure would be open to requests

2.5 years

The SARS-CoV-2 pandemic affected the recruitment rate, and the number of subjects who participated in and completed the investigation was few. Of those enrolled, there were many dropouts, e.g. due to leakage at the lid. The low number of evaluable study participants limited the assessment of the medical device performance.